INmune Bio: Harnessing The Power Of The Innate Immune System

  • Based on the theory that chronic low-grade inflammation is behind many ailments, the company’s therapies are setting out to enlist the innate immune system to combat these.
  • They have multiple shots at goal addressing large problems with few treatment options facing large market opportunities.
  • None of these are close to approval, although the company has cash for at least 18-24 months, possibly beyond that.
  • The recent retreat in the share price provides an opportunity, if you can tolerate the risk and have patience.
  • Learn More »